Stem cell-based therapies for brain injuries, such as traumatic brain injury (TBI), are a promising approach for clinical trials. However, technical hurdles such as invasive cell delivery and tracking with low transplantation efficiency remain challenges in translational stem-based therapy. This article describes an emerging technique for stem cell labeling and tracking based on the labeling of the mesenchymal stem cells (MSCs) with superparamagnetic iron oxide (SPIO) nanoparticles, as well as intranasal delivery of the labeled MSCs. These nanoparticles are fluorescein isothiocyanate (FITC)-embedded and safe to label the MSCs, which are subsequently delivered to the brains of TBI-induced mice by the intranasal route. They are then tracked non-invasively in vivo by real-time magnetic resonance imaging (MRI). Important advantages of this technique that combines SPIO for cell labeling and intranasal delivery include (1) non-invasive, in vivo MSC tracking after delivery for long tracking periods, (2) the possibility of multiple dosing regimens due to the non-invasive route of MSC delivery, and (3) possible applications to humans, owing to the safety of SPIO, non-invasive nature of the cell-tracking method by MRI, and route of administration.
Introduction
Mesenchymal stem cells (MSC) are attractive candidates for stem cell-based therapies in treatments of central nervous system (CNS) disorders and injuries in humans. Moreover, MSCs have been used as a vehicle for the delivery of therapeutic proteins at injury sites 1, 2 . In recent years, promising innovations have been developed to establish 1) novel routes of cell delivery and 2) cell tracking for stem cell-based therapies of CNS disorders. The intranasal delivery of stem cells into the brain depends on the ability of cells to bypass the cribriform plate and enter the olfactory bulb partially via a parenchymal route 3 . The combination of intranasal delivery and the labeling of MSCs with superparamagnetic iron oxide (SPIO) nanoparticles represents a promising approach for clinical applications of MSCs in treating CNS disorders, since SPIO nanoparticles are safe probes for magnetic resonance imaging (MRI) and allow non-invasive sensitive longitudinal tracking of MSCs post-delivery by MRI 3, 4, 5 . Furthermore, intranasal delivery is a safe and non-invasive route that allows repeated administration within a short period of time.
This article describes a highly sensitive and non-invasive technique for tracking MSCs in vivo post-intranasal delivery in a mouse model of traumatic brain injury (TBI), which employs SPIO-labeled cells and MRI. One important advantage of the SPIO labeling is the sensitive detection of SPIO in tissue by MRI, which makes it possible to track cells efficiently and non-invasively. The SPIO nanoparticles used here are commercially available and tagged with a fluorescein isothiocyanate (FITC) fluorophore, which allows for the detection of SPIO in tissue without immunostaining or additional processing. Furthermore, it is possible to perform longitudinal real-time tracking and investigate the biodistribution of the delivered MSCs. Figure 1B,C) . Alternatively, perform Prussian blue staining for the cells (see steps 6.2-6.4 for the staining protocol).
Labeling of MSCs with SPIO Nanoparticles
3. Harvest adherent cells by treatment with 3 mL of trypsin and incubate at 37 °C. After 5 min of incubation, add 7 mL of pre-warmed DMEM media with 10% FBS (v/v) to inactivate the trypsin. Collect the cell suspension using a pipette into a 15 mL conical tube. 4. Centrifugate the cell suspension at 300 x g for 5 min. Discard the supernatant and resuspend the cell pellet in PBS. Count the viable cells using trypan blue dye and a hemocytometer.
NOTE:
The cell pellet of the labeled cells will appear as a dark color due to iron loading ( Figure 1D ). This protocol is relevant for MSC labeling and MRI imaging. The procedure for MSC labeling 6 has been previously optimized, and only the steps to prepare labeled MSCs to track in vivo are included here, since in vivo tracking is the focus. The protocol for culturing and labeling of other cell types should be optimized by the researcher. 5. Adjust the cell concentration using PBS to 150,000 cells (or a number that results in a sufficient MRI signal) in 18 µL of PBS (or the total volume that will be used in the intranasal delivery procedure). NOTE: It was noticed that a cell concentration higher than 150,000 cells/18 µL of PBS leads to cell aggregation, which may affect the efficiency of intranasal delivery. If a higher number of cells is needed for intranasal delivery, increase the total volume of cell suspension and increase the number of intranasal administrations, as intranasal administration is a non-invasive procedure, and multiple dosing is possible.
Controlled Cortical Impact (CCI) Injury
NOTE: In this protocol, male C57 BL/6 mice (7-8 weeks old) were kept in a 12/12 h light/dark cycle with ad libitum access to food and water.
1. To prepare each mouse for CCI injury, administer the zolazepam (50 mg/kg) and xylazine (20 mg/kg) anesthetizing cocktail via intraperitoneal (i.p.) injection (1 mL/kg). Ensure that the depth of anesthesia is sufficient by a lack of toe-pinch response. Alternatively, place the mouse in a chamber supplied with 2%-4% isoflurane for 60 s. 2. Shave the fur of the dorsal surface of the skull between the ears using an electronic hair clipper. Clean the shaved area several times using a sterile cotton swab soaked in iodine. Use a cotton swab soaked in 70% ethanol to clean off the iodine. 3. Place the anesthetized mouse in the stereotactic frame and secure the mouse using ear bars and nose bars. Make a midsagittal incision (approximately 2.5 cm) in the shaved skin using sterile scissors to access the surface of the skull. 4. Remove the tissue on the bone using a cotton pad to expose the skull. Clean the skull surface using a cotton swab soaked in a 3% H 2 O 2 for 10 s, then clean it with a dry cotton pad.
NOTE:
The skull sutures and both bregma and lambda can now be easily identified. 5. Identify the coordinates of choice on the skull surface for the CCI injury and draw a circle (4 mm diameter) around the coordinates using a pencil or proper marker. NOTE: In this protocol, the coordinates at anteeroposterior (AP) -2.0 mm and mediolateral (ML) +1.5 mm were used for CCI induction. 6. Use a microdrill and round burr (0.5 mm diameter) to thin the skull at the marked circle. Avoid applying pressure while drilling, as drilling through the bone may cause damage to the brain parenchyma. Clean bone dust away using a clean and dry cotton swab. 7. Gently remove the bone flap using sterile fine forceps to expose the dura mater while keeping it intact. Remove the mouse from the stereotactic frame that was used for pre-injury preparation and place it into the stereotactic frame of the CCI device. 8. Stabilize the head of the mouse using the ear bars and nose bars. Make sure the head of the mouse is level in the rostral-caudal direction and adjust the nose bars, if needed. 9. Follow the instructions on the control box to zero the impactor tip to the exposed cortical surface. Make sure that the impactor tip is aligned directly above the desired cortex coordinates to be impacted using the X and Y control wheels on the base of the impactor. 10. Set the experiment parameters using the control box with a velocity of 5 m/s, dwell time of 250 ms, and injury depth of 1 mm to induce mild injury in the mouse. 11. Induce injury by pressing the ''impact'' button on the control box. Swab any bleeding that occurs using a sterile cotton swab. 12. Remove the mouse from the stereotactic frame and close the incision using silk surgical sutures. Do not use metal clips to close the surgical site, since the mouse will be subjected to a magnetic field for MRI. 13. Apply topical antibiotics (bacitracin neomycin) to the surgical site to prevent infections. Keep the mouse on the heating pad and monitor it closely during the recovery phase. 14. Administer ketoprofen (2.5 mg/kg, IP) daily for 3 days after surgery, unless the ketoprofen administration contradicts with the study goals.
1. To prepare the mouse for MRI scanning, anesthetize the mouse with isoflurane (5% isoflurane in 1 L/min of O 2 for induction, 1.5%-2% isoflurane for maintenance). Perform a toe-pinch to ensure that the mouse reaches the required anesthesia level. 2. Place the mouse on the imaging holder and secure its position using taps or any other proper method. Move the holder to the center of the MRI coil (7 T/40 cm magnet) and connect the monitoring connection. 3. To acquire T2*-weighted scans using a spin-echo sequence, set the repetition time (TR) to 1500 ms and echo time (TE) to 2.8 ms. 2. Embed the brain in the optimal cutting temperature (OCT) solution and freeze at -20 °C. Section the brain with a cryostat microtome into slices with 14 μm thickness and mount them onto slides. Store the sections slides at -20 °C until further use.
Prussian Blue Staining
NOTE: Prussian blue staining is commonly used to detect the iron content in SPIO-labeled cells. Here, Prussian blue staining is used to confirm that the hypointense signals in the MRI images correspond to the SPIO-labeled MSCs and not to artifacts. Prussian blue staining is one of the most sensitive histochemical methods used to detect iron in tissues and can be used to identify even a single granule of iron in the cells. 
Discussion
The protocol described here represents general procedures for the SPIO labeling of MSCs and MRI tracking of SPIO-labeled MSCs postintranasal delivery. The protocol allows the opportunity to study the migration and biodistribution of MSCs post-delivery in vivo in the brain, using a non-invasive method.
MSCs are attractive candidates for stem cell-based therapies for CNS disorders and injuries due to their ability to secrete trophic factors that 1) trigger neurorestorative processes and 2) provide neuroprotection, owing to their anti-inflammatory effects within the injury area 9, 10, 11, 12 . Although long-term MRI tracking and detection of SPIO-labeled MSCs may be limited due to the dilution of intercellular SPIO with cell division, labeled cells can be detected for up to several weeks post-transplantation in the brains of animal models 13 . Also described here is the labeling protocol of MSCs with SPIO nanoparticles coated with dextran without transfection agents. Other protocols have been used in the literature 14, 15, 16 . However, in all cases, these protocols should be adjusted for cell type, SPIO size, incubation time, and SPIO concentration. MSCs have been shown to have impaired chondrogenic differentiation potential but not adipogenic differentiation upon SPIO labeling 17 . Therefore, it is highly recommended that differentiation assays be performed prior to stem cell delivery to evaluate the influence of SPIO on the differentiation potency of stem cells. In a previous study, it was demonstrated that MSC labeling with the same SPIO type and concentration used in the here did not affect the osteogenic or adipogenic differentiation potency of MSCs 6 .
The intranasal route of therapeutic stem cell delivery for brain disorders and injuries is a promising approach for the clinical application of stem cells. However, the intrinsic and molecular mechanisms that dictate the behaviors of stem cells in the nasal cavity remain unclear. Although the intranasal route is widely explored for the delivery of small molecules, the size and biodistribution behavior of the therapeutic stem differ from small molecules. The current protocol demonstrates that MSCs tend to migrate toward the injury site after intranasal delivery.
Here, T2*-weighted images were used to track the SPIO-labeled MSCs. Other reports have used gradient echo imaging. However, susceptibility artefacts are often observed in gradient echo imaging due to intercellular SPIO. In the current protocol, the location of the hypointense areas representing the SPIO-labeled MSCs on T2*-weighted images was the same as the location of the SPIO in brain sections as detected by histological examination (Figure 3) . This indicates the adequate sensitivity of T2*-weighted spin echo imaging for SPIO-labeled MSC tracking in the brain. In summary, the described protocol is beneficial for in vivo stem cell tracking studies of brain injuries and disorders. The longitudinal tracking of stem cells in vivo has traditionally been performed by sacrificing animals at multiple timepoints. The current protocol provides a non-invasive and efficient approach for MSCs delivery and tracking, which represents a potential procedure for stem cell-based therapy for brain injuries and disorders in clinical settings.
